DHX38 Antibody

What is DHX38 and why is it important in biological research?

DHX38 (also known as DDX38, PRP16, PRPF16, or KIAA0224) is a member of the DEAD/H box family of splicing factors characterized by the conserved Asp-Glu-Ala-Asp (DEAD) motif. It functions as an ATP-binding RNA helicase involved in pre-mRNA splicing . DHX38 is critical for:

• Alteration of RNA secondary structure

• Translation initiation

• Nuclear and mitochondrial splicing

• Ribosome and spliceosome assembly

DHX38 has recently gained significance in research due to its association with several pathological conditions, including cancer and retinitis pigmentosa .

What antibody applications are available for DHX38 research?

Based on available research antibodies, DHX38 can be studied using multiple methodological approaches:

DHX38 antibodies are available in various formats with reactivity against human, mouse, and rat DHX38 proteins .

How should I validate a DHX38 antibody for my research?

Methodological validation should include:

• Positive and negative controls: Use tissues/cells known to express high levels of DHX38 (positive control) and those with minimal expression (negative control).

• Knockdown validation: Implement siRNA-mediated knockdown of DHX38 as performed in studies examining DHX38 function in cancer cells .

• Multiple detection methods: Compare results across different methods (e.g., western blot, immunofluorescence).

• Specificity testing: Evaluate cross-reactivity with related DEAD-box proteins.

• Antibody titration: Determine optimal antibody concentration for your specific application.

Research has utilized siRNA knockdown approaches with sequences such as 5' UCAGCUCACAGACCAAAGCGGtt 3' or SMART pool targeting sequences: GCACUGAUCUGGACUGUCA, GAUCGGGAUUGGUACAUGA, AUGCUAAGGCCAUGCGGAA, CCACUCAGCUGACGCAGUA to validate antibody specificity .

How can I design experiments to investigate DHX38's role in alternative splicing?

When studying DHX38's involvement in alternative splicing, consider these methodological approaches:

• DHX38 knockdown/overexpression followed by RNA-seq: This reveals global splicing changes and identifies specific regulated exons or introns. Research has shown DHX38 regulates intron retention in RELL2 pre-mRNA in pancreatic ductal adenocarcinoma (PDAC) .

• RNA immunoprecipitation (RIP): RIP-qPCR has been used to demonstrate that DHX38 binds to specific intron regions, such as the fourth intron region of RELL2 pre-mRNA .

• Splicing reporter assays: Implement HBB reporter assays to measure splicing efficiency with wild-type versus mutant DHX38 .

• RT-PCR analysis: Design primers flanking alternatively spliced regions to quantify splicing changes. For example, knocking down DHX38 increased RELL2 intron 4 retention, while overexpression decreased retention .

• Rescue experiments: Perform complementation with wild-type DHX38 following knockdown to confirm specificity of splicing defects.

What are the optimal experimental conditions for studying DHX38's interaction with R-loops?

R-loops (RNA/DNA hybrids) have been linked to DHX38 function in maintaining genomic integrity. To study this interaction:

• Immunofluorescence detection: Use S9.6 antibody to detect R-loops in single cells following DHX38 knockdown or mutation .

• RNase H overexpression: As a control, express RNase H (RNH1) to degrade R-loops and determine if phenotypes are R-loop dependent. Research shows RNase H1 overexpression rescues DNA damage caused by DHX38 deficiency .

• DNA damage assays: Implement γH2AX immunostaining and alkaline comet assays to measure DNA breaks associated with R-loop accumulation in DHX38-deficient cells .

• Replication stress analysis: Use IdU/CIdU labeling to visualize DNA replication progression and determine if DHX38 deficiency impairs DNA synthesis through R-loop formation .

• Cell cycle synchronization: Serum starvation to minimize DNA replication can help determine if DHX38-related DNA damage is replication-dependent .

How can I analyze the molecular consequences of disease-associated DHX38 mutations?

For investigating DHX38 mutations like those found in retinitis pigmentosa:

• Protein stability and localization: Compare wild-type and mutant protein half-life and subcellular distribution using tagged versions of DHX38.

• Protein-protein interactions: Perform co-immunoprecipitation with anti-GFP or anti-FLAG antibodies to identify changes in DHX38 interaction partners caused by mutations .

• ATPase activity assays: Measure the impact of mutations on DHX38's ATP hydrolysis function.

• In vivo models: Consider zebrafish models, as zebrafish Dhx38 shows 80% identity and 89% homology to human DHX38 .

• Splicing efficiency: Compare splicing outcomes between wild-type and mutant DHX38 using reporter constructs.

The missense variant c.971G>A; p.(Arg324Gln) identified in retinitis pigmentosa patients provides a model mutation for such studies .

What is the role of DHX38 in cancer and how can antibodies help investigate this connection?

DHX38 has contrasting roles in different cancer types:

• Tumor suppressor in PDAC: DHX38 inhibits PDAC progression by regulating RELL2 pre-mRNA splicing. Knockdown of DHX38 increased cell proliferation and decreased gemcitabine sensitivity .

• Oncogenic role in OCCC: DHX38/PRP16 is required for ovarian clear cell carcinoma tumorigenesis. Its knockdown induces apoptosis specifically in OCCC cells but not in normal ovarian surface epithelium cells .

Antibody-based research approaches should include:

• Tissue microarray analysis: Compare DHX38 expression across tumor samples and corresponding normal tissues.

• Patient-derived xenograft models: Evaluate DHX38 expression changes during tumor progression.

• Correlation studies: Relate DHX38 expression/localization to patient outcomes and treatment response.

• ChIP-seq analysis: Investigate genomic binding sites of DHX38 in cancer versus normal cells.

How does DHX38 contribute to retinitis pigmentosa and what experimental approaches are most effective for studying this relationship?

DHX38 mutations have been linked to early-onset autosomal recessive retinitis pigmentosa (arRP) . Effective experimental approaches include:

• Genetic analysis: Screen for DHX38 variants in arRP patients. A novel missense variant c.971G>A; p.(Arg324Gln) has been identified that segregates with the arRP phenotype with logarithm of the odds (LOD) scores of 5.0 and 4.3 in two Pakistani families .

• Zebrafish models: Dhx38 mutant zebrafish have revealed that DHX38 is necessary for retinal development through preventing R-loop-mediated replication stress and DNA damage. Immunostaining using γH2AX antibody has shown increased DNA double-strand breaks in dhx38 mutant retinas .

• Molecular mechanism studies: Investigate how DHX38 mutations affect:

  • RNA processing in photoreceptor cells

  • R-loop formation and DNA damage in retinal cells

  • Expression of retina-specific genes

• Rescue experiments: Test whether wild-type DHX38 expression can rescue retinal phenotypes in model systems.

What biomarkers correlate with DHX38 expression or function in disease contexts?

Several biomarkers have been associated with DHX38 function:

• R-loop markers: S9.6 antibody detection of R-loops serves as a biomarker for DHX38 dysfunction .

• DNA damage markers: γH2AX levels increase significantly when DHX38 is depleted or mutated .

• Splicing biomarkers: RELL2 intron 4 retention can serve as a readout of DHX38 activity in PDAC .

• Replication stress markers: Reduced DNA synthesis measured by IdU/CIdU labeling correlates with DHX38 deficiency .

• Apoptotic markers: In OCCC, DHX38 knockdown induces apoptosis markers like PUMA (p53 upregulated modulator of apoptosis) .

What are the optimal conditions for DHX38 immunoprecipitation experiments?

Based on published protocols, optimal conditions include:

• Lysis buffer composition: NET2 buffer (50 mM Tris–HCl pH 7.5, 150-300 mM NaCl, 0.05% IGEPAL CA-630) supplemented with RNasin and Protease Inhibitor Cocktail .

• Cell preparation: Wash cells 3x with PBS, harvest into PBS, and centrifuge at 1,000 g at 4°C for 10 minutes .

• Sample processing: Sonicate samples on ice bath (3x30 pulses; 0.5s for each pulse at 60% of maximum energy) and centrifuge at 20,000 g at 4°C for 10 minutes .

• Pre-clearing: Incubate lysates with Protein G Sepharose beads at 4°C for 2 hours .

• Antibody selection: For tagged DHX38, use goat anti-GFP antibodies or anti-FLAG M2 antibody (Sigma Aldrich, slbx2256) at 4°C for 4 hours .

• Controls: Include IgG control and input samples for validation.

How can I distinguish between DHX38's direct splicing effects and secondary consequences of its dysfunction?

This methodological challenge requires:

• Temporal analysis: Implement time-course experiments after DHX38 depletion to distinguish primary from secondary effects.

• Catalytically inactive mutants: Compare DHX38 knockout with expression of ATPase-deficient DHX38 to separate structural from enzymatic roles.

• Splicing junction analysis: Focus on intron retention events, which are likely direct targets of DHX38 activity, as demonstrated with RELL2 intron 4 .

• Direct binding assessment: Perform CLIP-seq (Cross-linking immunoprecipitation followed by sequencing) to identify direct RNA targets.

• Rescue experiments with specific splicing reporters: Test if wild-type DHX38 can rescue specific splicing events while mutant forms cannot.

• R-loop-dependent versus independent effects: Use RNase H1 overexpression to distinguish which phenotypes depend on R-loop accumulation .

What are the critical parameters for reproducible DHX38 knockdown experiments?

For reliable DHX38 knockdown:

• siRNA design: Use validated sequences like 5' UCAGCUCACAGACCAAAGCGGtt 3' or SMART pool targeting sequences .

• Transfection conditions: Use Oligofectamine reagent at final siRNA concentration of 50nM .

• Incubation time: Allow 72 hours with medium change at 48 hours post-transfection .

• Knockdown validation: Confirm at both mRNA (RT-qPCR) and protein levels (western blot).

• Control selection: Use appropriate negative control siRNAs, such as Negative control #5 from Ambion .

• Cell density: Maintain consistent cell density across experiments to control for growth-related effects.

• Rescue controls: Include rescue experiments with siRNA-resistant DHX38 constructs to confirm specificity.

What emerging techniques could advance our understanding of DHX38 function?

Several cutting-edge approaches show promise:

• CRISPR-based screens: Comprehensive CRISPR-Cas9 knockout screens have successfully identified DHX38 as critical for OCCC growth .

• Single-cell splicing analysis: To understand cell-type specific effects of DHX38 in heterogeneous tissues.

• Cryo-EM structural studies: To visualize DHX38 in the context of the spliceosome.

• Patient-derived organoids: To study DHX38 in disease-relevant 3D tissue models.

• In vivo CRISPR: For tissue-specific DHX38 knockout in animal models to understand its role in development and disease.

• Combinatorial drug screens: To identify potential therapeutic approaches for DHX38-related diseases.

How can researchers integrate DHX38 antibody data with other -omics approaches?

Integrative approaches should include:

• RNA-seq + proteomics: Correlate DHX38-dependent splicing changes with altered protein isoform expression.

• ChIP-seq + RNA-seq: Map DHX38 genomic binding sites in relation to alternative splicing outcomes.

• R-loop mapping + DHX38 binding: Integrate R-loop sequencing data with DHX38 RNA binding profiles.

• Multi-omics patient data: Correlate DHX38 expression/mutation status with transcriptome, proteome, and clinical outcomes.

• Network analysis: Place DHX38 within the broader context of splicing regulatory networks using protein-protein interaction data.